Lantheus to Present Osteosarcoma and Prostate Cancer Data at 2026 ASCO Meeting
Event summary
- Lantheus will present data on LNTH-2403, a LRRC15-targeted 177Lutetium-labeled monoclonal antibody, for relapsed/refractory osteosarcoma at the 2026 ASCO Annual Meeting.
- A poster session on June 1 will detail a phase 1/2 study evaluating safety, tolerability, and preliminary anti-neoplastic activity of LNTH-2403.
- Additional real-world data on piflufolastat F 18 in early-stage prostate cancer will be published only.
- Presenter Noah Federman from UCLA Jonsson Comprehensive Cancer Center will lead the osteosarcoma session.
The big picture
Lantheus' ASCO 2026 presentations highlight its focus on radiopharmaceuticals for hard-to-treat cancers, aligning with the growing demand for targeted therapies in oncology. The company's dual focus on osteosarcoma and prostate cancer reflects its strategy to diversify its pipeline beyond traditional imaging applications. Success in these areas could expand its market reach and reinforce its leadership in radiopharmaceuticals.
What we're watching
- Clinical Validation
- How the phase 1/2 data on LNTH-2403 will position Lantheus in the relapsed/refractory osteosarcoma market.
- Market Differentiation
- Whether the real-world data on piflufolastat F 18 can reinforce its use in early-stage prostate cancer treatment patterns.
- Regulatory Pathway
- The pace at which Lantheus advances LNTH-2403 through subsequent clinical phases following ASCO 2026.
Related topics